全球止咳药市场规模、份额、趋势及成长分析报告（2026-2034）

预计止咳药市场将从 2025 年的 17.3 亿美元成长到 2034 年的 25.8 亿美元，2026 年至 2034 年的复合年增长率为 4.59%。

由于呼吸道疾病和季节性疾病的日益普遍，导致持续咳嗽，全球止咳药市场正稳定成长。止咳药，俗称“咳嗽药”，透过作用于脑部和喉咙的咳嗽反射来缓解咳嗽。这些药物广泛用于治疗感冒、流感、支气管炎和其他呼吸道感染疾病的相关症状。人们对呼吸系统健康的日益关注也推动了对这些药物需求的成长。

市场成长受多种因素驱动，包括呼吸道感染疾病上升和环境污染加剧。气候变迁和都市区空气污染加剧了呼吸道疾病，导致止咳药使用量增加。此外，处方药和非处方药的普及也使消费者更容易获得治疗选择。製药公司也正在研发改良配方，以更快地缓解症状并延长药效。

鑑于全球健康意识的持续提升，止咳药市场前景光明。製剂创新和联合治疗可望提高呼吸道症状的治疗效果。新兴市场药品分销网络的拓展和医疗服务可近性的改善预计也将推动市场成长。由于呼吸系统疾病在全球范围内仍然普遍存在，对有效止咳药的需求预计将持续成长。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球止咳药市场：依药物类型划分

• 市场分析、洞察与预测
• Benzonatate
• Dextromethorphan

第五章 全球止咳药市场：依药物类别划分

• 市场分析、洞察与预测
• 中枢镇咳药
• 週边促效剂
• 其他的

第六章：全球止咳药市场：依给药途径划分

• 市场分析、洞察与预测
• 口服
• 吸入剂
• 其他的

第七章 全球止咳药市场：以剂型划分

• 市场分析、洞察与预测
• 糖浆
• 药片
• 其他的

第八章 全球止咳药市场：依适应症划分

• 市场分析、洞察与预测
• 感冒症状
• 疼痛
• 咳嗽
• 其他的

第九章 全球止咳药市场：依产品类型划分

• 市场分析、洞察与预测
• 非处方药
• 处方药

第十章 全球止咳药市场：依年龄组别划分

• 市场分析、洞察与预测
• 儿童
• 成人
• 老年人

第十一章 全球止咳药市场：依最终用户划分

• 市场分析、洞察与预测
• 医院
• 专科诊所
• 居家照护
• 其他的

第十二章 全球止咳药市场：依通路划分

• 市场分析、洞察与预测
• 医院药房
• 零售药房
• 网路药房
• 其他的

第十三章 全球止咳药市场：按地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第十四章 竞争格局

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十五章：公司简介

• 主要公司的市占率分析
• 公司简介
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc
  • Novartis AG
  • GlaxoSmithKline Plc
  • Sanofi
  • Johnson & Johnson Private Limited
  • Teva Pharmaceutical Industries Ltd
  • Sun Pharmaceutical Industries Ltd
  • Mylan NV
  • AstraZeneca
  • Bayer AG
  • Cipla Inc
  • Aurobindo Pharma
  • Hikma Pharmaceuticals PLC
  • Amneal Pharmaceuticals LLC

The Antitussive Drugs Market size is expected to reach USD 2.58 Billion in 2034 from USD 1.73 Billion (2025) growing at a CAGR of 4.59% during 2026-2034.

The global antitussive drugs market has grown steadily due to the increasing prevalence of respiratory conditions and seasonal illnesses that cause persistent coughing. Antitussive drugs, commonly known as cough suppressants, are used to reduce coughing by acting on the cough reflex in the brain or throat. These medications are widely used in treating symptoms associated with colds, flu, bronchitis, and other respiratory infections. Growing awareness about respiratory health has contributed to increased demand for these medications.

Market growth is driven by several factors, including the rising incidence of respiratory infections and environmental pollution. Changing weather conditions and urban air pollution can aggravate respiratory conditions, leading to increased use of cough suppressants. In addition, the availability of both prescription and over-the-counter antitussive medications has expanded consumer access to treatment options. Pharmaceutical companies are also developing improved formulations that provide faster symptom relief and longer-lasting effects.

The future of the antitussive drugs market appears positive as healthcare awareness continues to increase worldwide. Innovations in drug formulations and combination therapies may enhance treatment effectiveness for respiratory symptoms. Expanding pharmaceutical distribution networks and growing access to healthcare services in emerging markets are also expected to support market growth. As respiratory illnesses remain common globally, demand for effective cough suppression treatments is likely to continue.

MARKET SEGMENTATION

By Drug

• Benzonatate
• Dextromethorphan

By Drug Class

• Centrally Acting Drugs
• Peripherally Acting Drugs
• Others

By Route of Administration

• Oral
• Inhalational
• Others

By Dosage Form

• Syrup
• Tablet
• Others

By Indication

• Cold Symptoms
• Pain
• Cough
• Others

By Product Type

• Over-The-counter (OTC)
• Prescription Drug

By Age Group

• Pediatric
• Adult
• Geriatric

By End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

COMPANIES PROFILED

• F HoffmannLa Roche Ltd, Pfizer Inc, Novartis AG, GlaxoSmithKline plc, Sanofi, Johnson Johnson Private Limited, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Mylan NV, AstraZeneca, Bayer AG, Cipla Inc, Aurobindo Pharma, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ANTITUSSIVE DRUGS MARKET: BY DRUG 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug
• 4.2. Benzonatate Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Dextromethorphan Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ANTITUSSIVE DRUGS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Drug Class
• 5.2. Centrally Acting Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Peripherally Acting Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ANTITUSSIVE DRUGS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Inhalational Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ANTITUSSIVE DRUGS MARKET: BY DOSAGE FORM 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Dosage Form
• 7.2. Syrup Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Tablet Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ANTITUSSIVE DRUGS MARKET: BY INDICATION 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Indication
• 8.2. Cold Symptoms Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Pain Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Cough Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL ANTITUSSIVE DRUGS MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

• 9.1. Market Analysis, Insights and Forecast Product Type
• 9.2. Over-The-counter (OTC) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.3. Prescription Drug Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 10. GLOBAL ANTITUSSIVE DRUGS MARKET: BY AGE GROUP 2022-2034 (USD MN)

• 10.1. Market Analysis, Insights and Forecast Age Group
• 10.2. Pediatric Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 10.3. Adult Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 10.4. Geriatric Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 11. GLOBAL ANTITUSSIVE DRUGS MARKET: BY END-USERS 2022-2034 (USD MN)

• 11.1. Market Analysis, Insights and Forecast End-users
• 11.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 11.3. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 11.4. Homecare Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 11.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 12. GLOBAL ANTITUSSIVE DRUGS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 12.1. Market Analysis, Insights and Forecast Distribution Channel
• 12.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 12.3. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 12.4. Online Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 12.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 13. GLOBAL ANTITUSSIVE DRUGS MARKET: BY REGION 2022-2034 (USD MN)

• 13.1. Regional Outlook
• 13.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 13.2.1 By Drug
  • 13.2.2 By Drug Class
  • 13.2.3 By Route Of Administration
  • 13.2.4 By Dosage Form
  • 13.2.5 By Indication
  • 13.2.6 By Product Type
  • 13.2.7 By Age Group
  • 13.2.8 By End-users
  • 13.2.9 By Distribution Channel
  • 13.2.10 United States
  • 13.2.11 Canada
  • 13.2.12 Mexico
• 13.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 13.3.1 By Drug
  • 13.3.2 By Drug Class
  • 13.3.3 By Route Of Administration
  • 13.3.4 By Dosage Form
  • 13.3.5 By Indication
  • 13.3.6 By Product Type
  • 13.3.7 By Age Group
  • 13.3.8 By End-users
  • 13.3.9 By Distribution Channel
  • 13.3.10 United Kingdom
  • 13.3.11 France
  • 13.3.12 Germany
  • 13.3.13 Italy
  • 13.3.14 Russia
  • 13.3.15 Rest Of Europe
• 13.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 13.4.1 By Drug
  • 13.4.2 By Drug Class
  • 13.4.3 By Route Of Administration
  • 13.4.4 By Dosage Form
  • 13.4.5 By Indication
  • 13.4.6 By Product Type
  • 13.4.7 By Age Group
  • 13.4.8 By End-users
  • 13.4.9 By Distribution Channel
  • 13.4.10 India
  • 13.4.11 Japan
  • 13.4.12 South Korea
  • 13.4.13 Australia
  • 13.4.14 South East Asia
  • 13.4.15 Rest Of Asia Pacific
• 13.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 13.5.1 By Drug
  • 13.5.2 By Drug Class
  • 13.5.3 By Route Of Administration
  • 13.5.4 By Dosage Form
  • 13.5.5 By Indication
  • 13.5.6 By Product Type
  • 13.5.7 By Age Group
  • 13.5.8 By End-users
  • 13.5.9 By Distribution Channel
  • 13.5.10 Brazil
  • 13.5.11 Argentina
  • 13.5.12 Peru
  • 13.5.13 Chile
  • 13.5.14 Rest of Latin America
• 13.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 13.6.1 By Drug
  • 13.6.2 By Drug Class
  • 13.6.3 By Route Of Administration
  • 13.6.4 By Dosage Form
  • 13.6.5 By Indication
  • 13.6.6 By Product Type
  • 13.6.7 By Age Group
  • 13.6.8 By End-users
  • 13.6.9 By Distribution Channel
  • 13.6.10 Saudi Arabia
  • 13.6.11 UAE
  • 13.6.12 Israel
  • 13.6.13 South Africa
  • 13.6.14 Rest of the Middle East And Africa

Chapter 14. COMPETITIVE LANDSCAPE

• 14.1. Recent Developments
• 14.2. Company Categorization
• 14.3. Supply Chain & Channel Partners (based on availability)
• 14.4. Market Share & Positioning Analysis (based on availability)
• 14.5. Vendor Landscape (based on availability)
• 14.6. Strategy Mapping

Chapter 15. COMPANY PROFILES OF GLOBAL ANTITUSSIVE DRUGS INDUSTRY

• 15.1. Top Companies Market Share Analysis
• 15.2. Company Profiles
  • 15.2.1 F. Hoffmann-La Roche Ltd
  • 15.2.2 Pfizer Inc
  • 15.2.3 Novartis AG
  • 15.2.4 GlaxoSmithKline Plc
  • 15.2.5 Sanofi
  • 15.2.6 Johnson & Johnson Private Limited
  • 15.2.7 Teva Pharmaceutical Industries Ltd
  • 15.2.8 Sun Pharmaceutical Industries Ltd
  • 15.2.9 Mylan N.V
  • 15.2.10 AstraZeneca
  • 15.2.11 Bayer AG
  • 15.2.12 Cipla Inc
  • 15.2.13 Aurobindo Pharma
  • 15.2.14 Hikma Pharmaceuticals PLC
  • 15.2.15 Amneal Pharmaceuticals LLC